A Metabolic Cluster–Derived Risk Model for Prognostic Stratification, Immunometabolic Profiling, and Therapeutic Sensitivity Prediction in Prostate Cancer
This metabolic cluster–derived three-gene model may support prognostic stratification and characterization of immunometabolic heterogeneity in prostate cancer and provide a rationale for further investigation of potential treatment strategies.